Navigation Links
bioTheranostics' Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients
Date:12/10/2010

would respond to extended therapy with letrozole.  

Data from the study demonstrate that BCI is a prognostic biomarker for late recurrence  among ER-positive breast cancer patients. The data also confirm that HOXB13, part of the Breast Cancer Index, predicted patient benefit from letrozole among ER-positive breast cancer patients.

"For breast cancer patients and the medical professionals who treat them, this is a significant finding," said Dennis Sgroi, MD, Massachusetts General Hospital. "It is our understanding that this is the first time a biomarker has been validated exclusively in the 'late recurrence' setting.  It will be a valuable tool to help identify those patients whose disease will most likely recur, as well as those who will benefit from extended therapy."

"In combination with data from the Stockholm cohort presented at last year's SABCS, the data presented today reinforce BCI's unique prognostic value and application for long-term risk prognosis in the breast cancer setting," said Mark Erlander, PhD, chief scientific officer of bioTheranostics.

About bioTheranosticsAdvancing Molecular Diagnostics in OncologybioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community to support targeted disease management. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: Breast Cancer Index, which provides risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer; and the CancerTYPE ID® test, a cancer classification assay that provides molecular classification of cancers with indeterminate, uncertain, or differential diagnoses to aid in the determination of the
'/>"/>

SOURCE bioTheranostics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AltheaDx and Compendia Bioscience Launch the Breast Cancer Segregation Panel™
2. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
3. Reportlinker Adds Breast Cancer Drug Futures
4. LCS Constructors, Inc. Supports the Cure and Breast Cancer Awareness Month
5. Leading Journal Turns Up the Heat on Cutting-Edge Breast Cancer Treatment
6. K-State Research Team Investigates Mutated Genes Role in Breast Cancer
7. Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
9. Huiheng Medical, Inc. Announces Agreement to Acquire the ClearPath (TM) Breast Brachytherapy System
10. Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology
11. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, ... announced the closing of an underwritten public offering of 3,500,000 ... an aggregate 3,500,000 shares of common stock, at an offering ... warrants have a per share exercise price of $5.00, are ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument (Liquid ... Valves, Guages, Seals), Accessories, Services, End User (Biotechnology, ... provides a detailed overview of the major drivers, ... impacting the preparative and process chromatography market along ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... ... savvy suggestions for effective interactive healthcare marketing at Digital Pharma West. , ... (PRWEB) -- Viscira™, a leading ... relevant presentation entitled, “Maximizing Return on Interactive” at the Digital Pharma West (DPW) conference ...
... , July 7 Cardium Therapeutics (NYSE Amex: CXM ) today reported ... it has now resolved matters relating to the Company,s exchange listing compliance. , ... (Logo:   http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO ) , , ... , , , ...
... ... in their own lab with new Kinase Enzyme Systems from Promega and SignalChem. ... Madison, WI (PRWEB) ... flexible and complete kinase solution for the profiling of lead compounds against kinases representative ...
Cached Biology Technology:Viscira Delivers Key Presentation to Pharmaceutical Marketing Professionals at Leading Digital Industry Conference 2Cardium Regains Listing Compliance With NYSE Amex 2Cardium Regains Listing Compliance With NYSE Amex 3Cardium Regains Listing Compliance With NYSE Amex 4Promega Now Offers Complete Solution for Profiling Kinase Inhibitor Compounds Against the Human Kinome 2
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season ... as Acuity Market Intelligence reports that the long anticipated ... forecasts that intensifying demand for smart phones, tablets, and ... global market of 2.5 billion users with nearly 4.8 ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics company, today ... in genetic ancestry of individuals from across the ... more than four hundred years ago, the United ... peoples from different continents. This study illuminates how American history ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... N.Y. With support from the Photosynthetic Systems Division ... the School of Science at Rensselaer Polytechnic Institute are ... workings of the photosynthetic protein, Photosystem II. The high-impact ... photosynthesis for artificial use as an abundant source of ...
... Dec. 3, 2013 (Toronto) - People who carry a high-risk ... in childhood, decades before the illness appears, new research from ... The gene, called SORL1, is one of a number of ... the most common form of the illness. SORL1 carries the ...
... This news release is available in ... growing number of industries, workers are often unknowingly exposed to nanoparticles ... on health? Professor Denis Girard from the INRSInstitut Armand-Frappier Research Centre ... wide variety of NPs with a view to setting the record ...
Cached Biology News:Rensselaer researchers to map step-by-step mechanism of photosynthesis 2Rensselaer researchers to map step-by-step mechanism of photosynthesis 3Rensselaer researchers to map step-by-step mechanism of photosynthesis 4Alzheimer's risk gene may begin to affect brains as early as childhood, CAMH research shows 2Alzheimer's risk gene may begin to affect brains as early as childhood, CAMH research shows 3Thousands of new particles in workplaces despite large knowledge gap 2
... Maximize the value of your ... We offer the support you need ... using the most up to date ... with the Gene Expression Profiling Service ...
... the value of your microarray data ... the support you need from consultation ... most up to date methods. Utilize ... Gene Expression Profiling Service or from ...
... This CLS number is a new ... Cornings product number. If showing no ... old Sigma-Aldrich number (Z71,517-4) or contact ... cap polystyrene (expanded surface, easy grip) ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
Biology Products: